Pharmaceutical compound
| Clinical data | |
|---|---|
| Routes of administration | Intranasal |
.svg){kind=small}
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.
References
- "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
- Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
| Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development | |||||||||||
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Misplaced Pages by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Misplaced Pages by expanding it. |